Targeting MARCO in combination with anti-CTLA-4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming
Targeting MARCO as an additional checkpoint in the TME can offer a strategy to improve the antitumor efficacy of anti-CTLA-4 through a mechanism involving Mφ reprogramming rather than their depletion.
Authors
- James J. Mulé (ORCID: https://orcid.org/0000-0001-7354-0516)
- Hidenori Takahashi (ORCID: https://orcid.org/0000-0001-7872-1519)
- Rana Falahat (ORCID: https://orcid.org/0000-0001-7489-3807)
- Patricio Perez-Villarroel
Institutions
- Moffitt Cancer Center (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1136/jitc-2024-011030
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.27
Funders
- American Association for Cancer Research
- V Foundation for Cancer Research
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- National Institutes of Health
- National Cancer Institute